@Article{ecn.2025.0500,
AUTHOR = {Fu Zhang, Miao Lin, Yuancong Jiang, Fangjian Zhou},
TITLE = {The role of IL-33 in immunotherapy for breast cancer: targets and  signalling pathways},
JOURNAL = {European Cytokine Network},
VOLUME = {36},
YEAR = {2025},
NUMBER = {1},
PAGES = {1--5},
URL = {http://www.techscience.com/ECN/v36n1/64876},
ISSN = {1952-4005},
ABSTRACT = {Interleukin-33 (IL-33), a key member of the IL-1 family, plays a significant role in inflammation and cancer. Its classic receptors, ST2 and IL-1 receptor accessory protein (IL-1RAcP), are predominantly expressed in immune cells such as T helper 2 (Th2) cells and mast cells. Recent studies have highlighted the involvement of IL-33 in breast cancer, demonstrating its ability to exert dual functional effects by modulating both innate and adaptive immune responses within the tumour microenvironment. However, the precise molecular mechanisms linking IL-33 to breast cancer pathogenesis and its potential as a target for molecularly targeted therapies remain incompletely understood. This review aims to provide a comprehensive summary of the current understanding of IL-33 in breast cancer immunotherapy.},
DOI = {10.1684/ecn.2025.0500}
}